Who are Magnesium sulfate and then Digoxin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/magnesium-sulfate-and-then-digoxin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Magnesium sulfate and then Digoxin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Magnesium sulfate and then Digoxin (Magnesium sulfate and then Digoxin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Electrolyte supplement and cardiac glycoside combination. Area: Cardiovascular.

phase 3 Electrolyte supplement and cardiac glycoside combination Na+/K+-ATPase (digoxin); magnesium-dependent ion channels and enzymes (magnesium sulfate) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Magnesium sulfate and then Digoxin (Magnesium sulfate and then Digoxin) — Sunnybrook Health Sciences Centre. Magnesium sulfate reduces cardiac arrhythmias and electrolyte imbalance, while digoxin increases cardiac contractility and slows atrioventricular conduction.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Magnesium sulfate and then Digoxin TARGET	Magnesium sulfate and then Digoxin	Sunnybrook Health Sciences Centre	phase 3	Electrolyte supplement and cardiac glycoside combination	Na+/K+-ATPase (digoxin); magnesium-dependent ion channels and enzymes (magnesium sulfate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Electrolyte supplement and cardiac glycoside combination class)

Sunnybrook Health Sciences Centre · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Magnesium sulfate and then Digoxin — Competitive Intelligence Brief. https://druglandscape.com/ci/magnesium-sulfate-and-then-digoxin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab